Phase II Trial Of Neoadjuvant Bevacizumab With Modified FOLFOX7 In Patients With Stage II And III Rectal Cancer
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 19 Jun 2019
Price : $35 *
At a glance
- Drugs Bevacizumab (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Rectal cancer
- Focus Therapeutic Use
- 17 Jun 2019 Planned primary completion date changed from 2 Aug 2019 to 31 Dec 2019.
- 31 Aug 2018 Biomarkers information updated
- 23 May 2018 Planned End Date changed from 2 Aug 2019 to 2 Aug 2020.